6 citations,
January 2022 in “Journal of Investigative Dermatology”
Male pattern baldness is linked to higher levels of a certain receptor in the scalp, which leads to the shrinking of blood vessels and hair loss. Early treatment targeting this receptor could be more effective.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology”
The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
The user is considering switching from finasteride to dutasteride for hair loss. They are unsure if GT20029 can regrow hair, particularly on the temples. Another user mentions that regrowth on finasteride can take up to 2 years.
Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.